Refractory thyroid cancer: a paradigm shift in treatment is not far off

Editorial

David G Pfister et al. J Clin Oncol. 2008.

. 2008 Oct 10;26(29):4701-4.

doi: 10.1200/JCO.2008.17.3682. Epub 2008 Jun 9.

No abstract available

Comment on

Phase II trial of sorafenib in advanced thyroid cancer.
Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS. Gupta-Abramson V, et al. J Clin Oncol. 2008 Oct 10;26(29):4714-9. doi: 10.1200/JCO.2008.16.3279. Epub 2008 Jun 9. J Clin Oncol. 2008. PMID: 18541894 Free PMC article. Clinical Trial.
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Cohen EE, et al. J Clin Oncol. 2008 Oct 10;26(29):4708-13. doi: 10.1200/JCO.2007.15.9566. Epub 2008 Jun 9. J Clin Oncol. 2008. PMID: 18541897 Free PMC article. Clinical Trial.